Prostate cancer

Researchers are testing whether immediate curative treatment (surgery or radiotherapy, with or without hormone therapy) helps men aged 75 and older with high-risk, non-metastatic prostate cancer live longer and with better quality of life compared to conservative, symptom-focused…

Researchers are testing a procedure called irreversible electroporation in men with localized prostate cancer. The technique uses electrical pulses to destroy cancer cells in the prostate while aiming to avoid damage to nearby nerves and structures. The study will follow 10 men f…

Researchers are testing a radioactive drug called terbium-161 PSMA-I&T in men with metastatic castration-resistant prostate cancer, a form of the disease that has spread and no longer responds to hormone therapy. The drug attaches to a protein on prostate cancer cells and deliver…

This study tests whether using a special PET scan (PSMA-PET) to guide radiation can reduce short-term side effects in men whose prostate cancer returns after surgery. About 54 men will receive targeted radiation to the pelvis plus a boost to spots seen on the scan, along with sta…

This phase II trial is testing whether a combination of three drugs—cabozantinib, nivolumab, and ipilimumab—can shrink or slow the growth of rare genitourinary cancers that have spread. About 314 adults with these uncommon tumors will receive the drugs. The goal is to see if the …

This phase II trial tests whether adding a targeted radiation drug (177Lu-PSMA-617) to standard hormone therapy, with or without additional hormone-blocking pills, can better control low-volume metastatic hormone-sensitive prostate cancer. The study enrolls men whose cancer has s…

This early-phase trial tests a new drug, GSK5458514, designed to help the immune system attack prostate cancer cells. It is for men with metastatic castration-resistant prostate cancer that has spread and stopped responding to hormone therapy. The study will first find a safe dos…

This study compares a new boost approach called irreversible electroporation (IRE) using the NanoKnife system against the standard radiation boost for men with intermediate-risk prostate cancer. All participants will receive standard stereotactic body radiation therapy (SBRT), bu…

This phase II trial tests whether adding an experimental drug called PDS01ADC to standard radiation and hormone therapy can help the immune system fight prostate cancer. About 65 men with high- or intermediate-risk prostate cancer that hasn't spread will take part. Some will get …

Researchers are testing whether daily adaptive radiotherapy, which adjusts the radiation plan to each day's anatomy, causes fewer bladder and bowel side effects than standard radiotherapy in people with intermediate or high risk localized prostate cancer. The trial also compares …

This study tests whether adding the drug saruparib to standard radiation and hormone therapy can delay the spread of cancer in 700 men with high-risk prostate cancer that has a BRCA gene mutation. Participants will receive either saruparib or a placebo alongside their usual treat…

This study is testing a new drug called ADI-PEG20, which breaks down arginine (a nutrient cancer cells need), together with two chemotherapy drugs (carboplatin and cabazitaxel) in men with aggressive variant prostate cancer. The goal is to find the safest dose and check for side …

Researchers are testing a combination of two experimental drugs, JANX013 and JANX007, in men with metastatic castration-resistant prostate cancer, an advanced form that keeps growing despite hormone-lowering treatment. The Phase 1 trial gives both drugs by intravenous infusion to…

This trial investigates whether high doses of testosterone can shrink tumors in men with metastatic prostate cancer that no longer responds to standard hormone therapy and has mutations in DNA repair genes like ATM or CDK12. Participants receive monthly injections of high-dose te…

Researchers are testing a treatment plan for men with high-risk localized prostate cancer that combines whole-pelvis radiation given in five sessions, a high-dose radiation boost directly to the prostate, and two years of androgen deprivation therapy. The study aims to see how of…

This phase II trial is testing a focused, high-dose radiation therapy (SBRT) given in just two sessions for men with early-stage prostate cancer that hasn't spread. The goal is to see if this approach can destroy the tumor while avoiding the side effects of treating the whole pro…

This study investigates whether precisely targeted radiotherapy can delay the need for stronger drugs in men with prostate cancer that has started to grow in a few new spots while on systemic therapy. Participants have metastatic hormone-sensitive or castration-resistant prostate…

This phase 2 trial is testing an experimental drug called patritumab deruxtecan (HER3-DXd) in 740 people with advanced solid tumors, including melanoma, lung, breast, and other cancers. The drug is given by IV every three weeks. The main goal is to see if the drug shrinks tumors.…

Researchers are comparing two sequences of treatment for metastatic castration-resistant prostate cancer that carries certain DNA repair gene mutations. Participants receive either carboplatin first and olaparib second, or olaparib first and carboplatin second, switching after th…

This study tests a new way to deliver radiation therapy for early-stage prostate cancer. Instead of two separate sessions days apart, both radiation doses are given just three hours apart on the same day. The goal is to see if this is safe and could make treatment more convenient…

This study tests a new drug called opevesostat (plus hormone replacement therapy) against two standard treatments (abiraterone or enzalutamide) in about 1,300 men with metastatic castration-resistant prostate cancer that got worse after one prior hormone therapy. The goal is to s…

This study tests a new drug called HRS-5041, taken as a pill, combined with other cancer treatments for men with advanced prostate cancer. The goal is to see if the combination is safe and helps control the cancer. About 100 men aged 18 to 80 will take part. The study is currentl…

This study is for men with a type of advanced prostate cancer that no longer responds to hormone therapy and has spread to other parts of the body. It compares a new targeted drug, ifinatamab deruxtecan, to standard chemotherapy (docetaxel) to see which helps people live longer a…

This early-stage trial is testing a new drug called BL-M14D1 in about 120 people with advanced small cell lung cancer or other neuroendocrine cancers that have spread or cannot be removed. The drug works by homing in on a protein called DLL3 found on these cancer cells and delive…

This early-phase trial is testing a new drug called GSK5471713 in 54 men with metastatic castration-resistant prostate cancer that has worsened despite standard treatments. The study aims to find a safe dose and see if the drug can shrink tumors or lower PSA levels. It is the fir…

This early-stage trial tests a new drug that delivers radiation directly to prostate cancer cells. It is for men with metastatic castration-resistant prostate cancer, a form that has stopped responding to hormone therapy. The study will check for side effects and see if the drug …

This early-phase trial is testing a new drug called xaluritamig (AMG 509) in 40 adults with metastatic castration-resistant prostate cancer, a type that has spread and no longer responds to hormone therapy. The main goal is to check the drug's safety and how it moves through the …

This study tests a new drug called rezatapopt (PC14586) in people with advanced solid tumors that have a specific TP53 Y220C mutation. The drug is designed to reactivate the p53 protein, which normally helps stop cancer growth. The trial will also test rezatapopt combined with th…

This early-phase trial tests SL-28, a cell therapy made from donor immune cells, in 60 people with advanced solid tumors (like lung, pancreatic, or breast cancer) that haven't responded to standard treatments. The study aims to find a safe dose and see if the therapy can shrink t…

Researchers are testing whether men with high-risk localized prostate cancer can safely receive a shorter course of hormone therapy alongside focused, dose-escalated radiation to the prostate. The trial enrolls 30 men and uses an AI-based classifier to help tailor treatment. All …

This study tests a gene therapy called aglatimagene besadenovec, given with valacyclovir, in 45 men with intermediate-risk prostate cancer who will also receive radiation. The main goal is to see how the therapy spreads in the body and to measure immune responses and tumor marker…

This study is for men with prostate cancer that has spread to a few other parts of the body at diagnosis. It tests whether adding radiation therapy directly to those cancer spots (called metastasis-directed radiotherapy) can help keep the cancer under control longer than the usua…

This study tests whether adding a short, 30-day course of the oral hormone drug Relugolix to standard targeted radiation (SBRT) works better than radiation alone for men with intermediate-risk prostate cancer. About 60 men will be randomly assigned to one of the two treatments. T…

This early-stage trial tests a new oral drug called INR731, alone or with standard hormone therapy drugs, in 208 men with metastatic prostate cancer that no longer responds to hormone treatment. The main goals are to check safety, find the right dose, and see if the drug shows an…

This trial tests whether wrapping the nerves around the prostate with a special tissue allograft during surgery can reduce erectile dysfunction and incontinence. 25 men with localized prostate cancer will receive the wrap during nerve-sparing prostate removal. The study focuses o…

This phase 3 trial is testing whether adding the experimental drug xaluritamig to standard abiraterone helps men with metastatic castration-resistant prostate cancer live longer. About 750 participants who have not yet had chemotherapy will be randomly assigned to receive either …

This study tests whether a 16-week supervised exercise program (circuit training with resistance, functional, and aerobic exercises) can improve frailty and muscle loss in 80 men with metastatic prostate cancer who are on hormone therapy. Participants must be pre-frail or frail. …

This early-stage study tests a new drug called VIR-5500 in people with advanced prostate cancer that has stopped responding to hormone treatment. The main goals are to check the drug's safety and find the right dose, while also seeing if it can shrink tumors or lower PSA levels. …

This study tests a combination of two drugs—pembrolizumab (an immunotherapy) and 177Lu-PSMA-617 (a targeted radiation therapy)—in men with advanced prostate cancer that has stopped responding to hormone treatments. The goal is to see if this combo can slow or stop cancer growth. …

This study compares a new, shorter radiation treatment (5 sessions over 2 weeks) to the standard longer course (20-45 sessions over 4-9 weeks) for men with high-risk prostate cancer. The goal is to see if the shorter approach works just as well at preventing the cancer from sprea…

This phase 2 trial tests an oral drug called pacritinib in 32 men with metastatic castrate-resistant prostate cancer that has worsened after standard treatments. The drug is taken twice daily, and the main goal is to see if it can delay cancer growth for at least six months. Part…

This trial tests whether a combination of a daily erectile medication, pelvic floor exercises, aerobic exercise, dietary advice, and mental health support can improve erectile function and urinary control in men after robot-assisted prostate removal for prostate cancer. Sixty-fou…

This trial is testing a daily adaptive radiation therapy for low to intermediate risk prostate cancer that spares the urethra. The goal is to reduce urinary side effects compared to standard radiation. About 132 participants will receive this tailored radiation, and their urinary…

This early-stage trial tests AGX101, a drug that delivers chemotherapy directly to cancer cells by targeting a protein called TM4SF1. About 80 adults with advanced solid tumors (like breast, prostate, or pancreatic cancer) who have run out of standard options will receive the dru…

This study tests an experimental drug called AZD8359 for men with metastatic prostate cancer that has spread and is no longer responding to standard treatments. The drug is designed to guide the body's immune cells to attack cancer cells. The trial will first find the safest dose…

This study is for men with a type of advanced prostate cancer that has spread and no longer responds to standard hormone therapy. It tests whether adding a new drug called SX-682 to the existing drug apalutamide is safe and can shrink tumors or slow the cancer. About 78 men will …

This early-stage trial is testing an experimental drug called SHR-6914 in men with prostate cancer that has spread to other parts of the body. The main goal is to see if the drug is safe and tolerable, and to find the right dose for future studies. Participants must have a confir…

This early-stage trial is testing an experimental oral drug called RO7656594 in people with advanced or metastatic prostate cancer that has progressed after standard treatments. The study aims to find safe doses and check for any signs that the drug can shrink tumors or lower PSA…

This early-stage trial tests a new drug called LY4052031, which is designed to deliver a cancer-killing agent directly to tumor cells that have a protein called Nectin-4. The study includes 420 adults with advanced or metastatic solid tumors such as bladder, breast, lung, and oth…

This study tests a new drug, LY4257496, that delivers radiation directly to cancer cells with a specific protein (GRPR). It is for adults with advanced solid tumors like breast, prostate, or colorectal cancer that have not responded to other treatments. The goal is to see if the …

This phase 3 trial is testing whether giving men with metastatic prostate cancer half the standard dose of certain hormone therapies (called ARPIs) can be just as effective as the full dose, while causing less fatigue and fewer treatment stoppages. About 1,500 men with prostate c…

This study tests a new drug called GDC-1261 in 260 people with advanced or metastatic prostate cancer that has worsened after prior treatment. The goal is to check the drug's safety, find the best dose, and see if it can shrink tumors or lower PSA levels. Participants must alread…

This early-stage study tests an experimental drug called IMGS-001 in about 105 people with advanced solid tumors that have come back or not improved after standard treatments. The goal is to find a safe dose and see if the drug can shrink tumors. The study has two parts: first, t…

This early-stage trial tests a new radioactive drug called 177Lu-FC516 in 13 men with advanced prostate cancer that has stopped responding to standard treatments. The drug is given every 6 weeks for up to 4 cycles. The main goals are to find the safest dose and check for side eff…

This early-phase trial tests two radioactive drugs, [177Lu]Lu-A9-0631 and [225Ac]Ac-A9-0642, in people with advanced solid tumors that have a protein called GRPR on their surface. These cancers include certain breast, prostate, and colorectal cancers that have stopped responding …

This study tests a new way to give radiation for prostate cancer using only 2 treatments instead of the usual 39. Doctors will use MRI scans to see how the tumor responds after the first dose, then adjust the second dose to target the cancer more precisely. The goal is to see if …

This early-stage trial is testing a new biologic drug, JANX014, in 43 men with metastatic castration-resistant prostate cancer that has progressed after other treatments. The main goal is to check safety and find the right dose, while also looking at how the drug moves through th…

This study tests whether adding an experimental drug called PDS01ADC to standard chemotherapy (docetaxel) can help men with prostate cancer that has spread to other parts of the body. About 86 men with either castration-sensitive or castration-resistant metastatic prostate cancer…

This study tests whether adding an injected drug (PDS01ADC) to a daily pill (enzalutamide) can better control PSA levels in men whose prostate cancer has returned after initial treatment. About 65 participants will receive either enzalutamide alone or both drugs for 3 months, wit…

This phase II trial tests whether 6 months of androgen deprivation therapy (ADT) combined with dose-escalated radiotherapy can reduce the risk of distant metastasis in men with high-risk prostate cancer who have lower ARTERA scores. Participants receive standard ADT (degarelix, l…

This phase 2 trial tests ASP5541, a new injectable form of the hormone therapy abiraterone, in men with advanced prostate cancer that has spread. The study compares ASP5541 (given every 12 weeks) to daily abiraterone pills, both with or without steroids. About 218 men with metast…

This phase 3 trial is testing whether adding an experimental drug called rinzimetostat to the standard drug darolutamide can slow the progression of metastatic castration-resistant prostate cancer better than current treatments. The study enrolls men whose cancer has worsened aft…

This study tests an experimental drug called AZD6621 for men with metastatic prostate cancer that has spread. The drug is designed to help the body's immune cells attack cancer cells. The trial has two parts: first, finding the safest dose, then testing that dose in more people t…

This study tests whether adding the chemotherapy drug docetaxel to the usual hormone therapy and apalutamide helps men with prostate cancer that has spread to other parts of the body live longer. About 1,260 men will be randomly assigned to receive either the three-drug combinati…

This study tests whether analyzing a patient's tumor DNA and RNA can help doctors select the most effective treatment for advanced prostate cancer that no longer responds to hormone therapy. About 474 participants will receive one of several drugs based on their genetic profile. …

This phase 3 trial for men with advanced, hormone-resistant prostate cancer tests whether giving the drug lutetium-177 PSMA less often (only when the disease shows signs of activity) can improve quality of life without shortening survival. About 1,500 participants will be randoml…

This study tests whether adding a drug called relacorilant to standard hormone therapy and enzalutamide can better shrink high-risk prostate cancer before surgery. About 90 people whose cancer has not responded to standard treatments will take the study drugs for 24 weeks, then h…

This study tests a drug called tarlatamab in people with a specific type of advanced prostate cancer (DLL3-positive) that has spread and either came back or didn't respond to prior treatments. About 32 participants will receive the drug to see if it can shrink tumors or slow the …

This early-stage trial is testing an experimental drug called JNJ-98768111 in people with advanced prostate cancer that has spread to other parts of the body. The drug is designed to seek out and attach to a protein called KLK2 on prostate cancer cells, delivering a toxic agent d…

This study tests an experimental oral drug called HLD-0915 in men with metastatic prostate cancer that has worsened after other treatments. The trial has two phases: Phase 1 checks safety and the best dose, while Phase 2 looks at how well it controls the cancer. About 190 men wil…

This phase 1 trial tests an experimental oral drug called HRS-5041 in men with metastatic castration-resistant prostate cancer, a form of the disease that keeps growing despite hormone therapy. Researchers aim to find the safest dose, measure how the body processes the drug, and …

This study tests a new drug called AZD0516, given alone or with other cancer drugs, in people with metastatic prostate cancer that has spread. The main goals are to check safety, find the best dose, and see early signs of tumor control. About 177 participants will take part acros…

This study tests a daily herbal supplement called INM176 (made from Angelica Gigas Nakai) in 45 men with prostate cancer whose PSA levels are rising after prior treatment or who are on active surveillance. The goal is to see if the supplement is safe and can stabilize or lower PS…

This early-phase study tests two experimental drugs (JNJ-87189401 and JNJ-78278343) that help the immune system attack prostate cancer cells. The study involves about 355 men with advanced prostate cancer. The main goal is to find the safest dose and check for side effects.

This early-stage study tests BPX-601, a personalized CAR T cell therapy made from a patient's own immune cells, for advanced prostate cancer that has spread and stopped responding to other treatments. The trial will enroll 36 people to find the safest dose and check for side effe…

This early-phase study tests a new combination of two drugs for men with advanced prostate cancer that has spread and stopped responding to standard hormone therapy. The first drug helps the immune system attack cancer cells, and the second aims to make the immune system work bet…

This study looks at whether irreversible electroporation (IRE) can safely and effectively treat recurrent pelvic tumors in people who cannot have surgery, radiation, or other local treatments. IRE uses electrical pulses to destroy cancer cells without cutting or heating tissue. R…

This study tests two types of targeted radiation therapy (177Lu-PSMA-617 and 225Ac-PSMA-617) in 45 men with high-risk prostate cancer who are scheduled for prostate removal surgery. The goal is to see which therapy delivers more radiation to the tumor and how it affects the immun…

This study tests whether giving an extra, focused dose of radiation to the main tumor inside the prostate can improve cancer control in men with intermediate- or high-risk localized prostate cancer. Participants receive standard moderately hypofractionated radiotherapy (62 Gy in …

This Phase 3 trial tests whether adding a radioactive drug called AAA817 to standard hormone therapy can slow cancer growth better than current treatments alone. About 940 men with PSMA-positive metastatic castration resistant prostate cancer will be randomly assigned to receive …

This study is testing two experimental drugs (AZD9574 and AZD2265) together in people with metastatic prostate cancer that has spread beyond the prostate. The goal is to see if the combination is safe and can shrink tumors or lower PSA levels. About 152 adults whose cancer has no…

This study tests a new drug called AZD2265, which delivers radiation directly to prostate cancer cells. It is for people with a type of advanced prostate cancer that no longer responds to hormone therapy. The trial compares the new drug to standard treatments to see if it can slo…

This trial tests whether a special PET-CT scan can spot aggressive prostate cancers that standard MRI fails to see. Men aged 50 and older with intermediate-risk prostate cancer and at least one MRI-invisible tumor will receive the scan; if it lights up the hidden cancer, they wil…

This study is testing the drug T-DXd (Enhertu) in 100 adults with advanced HER2-positive solid tumors who have already tried other treatments and have no good options left. The goal is to see how well the drug works in real-world settings, including how many patients respond and …

This phase 2 trial tests whether adding the targeted drug capivasertib to standard hormone therapy can shrink or destroy high-risk prostate tumors before surgery. The study enrolls 30 men with PTEN-loss prostate cancer, a marker of resistance to standard treatment. Participants r…

This phase 2 trial is testing whether an investigational oral drug called MRT-2359, when combined with the standard prostate cancer drug apalutamide, can lower PSA levels in men with castration-resistant prostate cancer. The study includes about 25 adults with a specific genetic …

This study tests whether the drug talazoparib, given alone or with enzalutamide, can slow down cancer growth in men with a certain type of advanced prostate cancer that has stopped responding to a previous treatment called abiraterone. About 126 participants with specific gene ch…

This study is testing whether using MRI or CT scans to guide radiation therapy in real time can reduce urinary and bowel side effects for men who need radiation after prostate removal surgery. The treatment, called stereotactic body radiotherapy (SBRT), delivers precise high-dose…

This study tests a new oral drug called pocenbrodib, alone or with another drug (darolutamide), in 120 men with metastatic castration-resistant prostate cancer (mCRPC). The goal is to find safe doses and see if the combination can slow cancer growth. It is an early-stage trial, s…

This trial tests a combination of two advanced radiation techniques for men with intermediate- to high-risk prostate cancer that has not spread beyond the prostate. One technique, high-dose rate brachytherapy, places radioactive material directly into the tumor. The other, stereo…

This trial is testing whether adding the chemotherapy drug docetaxel after standard treatment (radiation or surgery) can improve outcomes for men with a particularly aggressive form of prostate cancer (Gleason score 9-10). Participants will either receive standard treatment alone…

This phase II trial tests a new radiation technique for low to intermediate risk prostate cancer. It uses an MRI-guided 'microboost' to deliver a higher dose to the tumor while lowering the dose to the rest of the prostate. The goal is to see if this approach is safe and causes f…

This registry tracks 2,500 men with prostate cancer who receive Vanquish therapy, a procedure that uses water vapor (steam) to destroy cancerous tissue. The goal is to see how well it controls the disease and what side effects occur over time in real-world settings. Participants …

This trial compares two treatment approaches for men with aggressive, metastatic prostate cancer that has stopped responding to hormone therapy and docetaxel. One approach uses a combination of two chemotherapy drugs (cabazitaxel and carboplatin), while the other uses a radioacti…

This phase 3 trial is testing whether adding low-intensity shockwave therapy to standard erectile dysfunction pills helps men recover erectile function more effectively after robotic prostate cancer surgery. The study involves 158 men who have undergone nerve-sparing surgery and …

This trial tests whether tailoring prostate cancer therapy to the genetic makeup of a person's tumor can improve the response before surgery. Men with high-risk localized prostate cancer receive initial hormone therapy while their tumor is genetically analyzed, then are assigned …

This study tests an experimental drug called AZD9574, taken alone or with other anti-cancer medicines, in about 695 people whose advanced solid tumors have grown despite prior treatment. The main goals are to check the drug's safety and find the right dose. Researchers will also …

This trial is testing whether adding surgery to remove the prostate to standard drug therapy helps men with advanced, hormone-sensitive prostate cancer that has spread to multiple sites. Participants will receive either the usual drug treatment alone or the same drugs plus surger…

This study tests whether taking darolutamide (a hormone-blocking pill) plus standard hormone therapy for 12 or 24 weeks before prostate removal surgery can reduce or eliminate cancer in men with high-risk localized prostate cancer. About 250 men in China will be randomly assigned…

This study tests a new drug called AZD9750, alone or with another drug (saruparib), in 300 men with metastatic prostate cancer that has progressed despite standard treatments. The goal is to check safety, find the right dose, and see if it can lower PSA levels, a marker of cancer…

This study looks at men with high-risk prostate cancer who will receive radiation therapy along with hormone therapy for either 6 months or 18 months. The goal is to see if the shorter treatment works as well at preventing cancer from coming back or getting worse over 5 years. Pa…

This phase III trial is testing whether adding the drug darolutamide and a precise, high-dose radiation technique (SBRT) to standard hormone therapy and radiation can help men with high-risk localized prostate cancer live longer without the cancer spreading. About 700 men will be…

This study looks at men whose prostate cancer has spread to a few spots in the body (oligometastatic). It compares standard radiation and hormone therapy alone versus adding the drug abiraterone for 8-9 months. The goal is to see if the extra drug improves quality of life and del…

This study tests whether giving abemaciclib before a radioactive drug (177Lu-PSMA-617) can make prostate cancer cells more sensitive to radiation. About 30 men with advanced, treatment-resistant prostate cancer will receive abemaciclib pills for two weeks, then the radioactive th…

This trial tests whether the drug rezvilutamide, taken alone for 48 weeks after prostate removal surgery, can prevent cancer from coming back in men at high risk of recurrence. Standard treatment often includes long-term hormone therapy with significant side effects. The study ai…

This study is testing whether adding a focused radiation boost after standard short-course radiotherapy improves outcomes for men with localized prostate cancer. About 1,200 men will be randomly assigned to receive either standard SBRT alone or SBRT plus one of three boost method…

This clinical trial is for men with prostate cancer that has spread to nearby pelvic lymph nodes but not further. It compares two radiation strategies: one that gives a higher dose to the prostate only, and another that boosts both the prostate and the affected lymph nodes. All p…

This phase 2 trial is testing whether combining a 12-month course of the hormone therapy Relugolix with precise, image-guided radiation can help men with intermediate-risk prostate cancer recover erectile function. Fifty men will receive the treatment and complete questionnaires …

This study investigates whether using magnetic resonance imaging (MRI) instead of standard CT scans to plan radiation therapy can improve treatment accuracy and reduce side effects. It enrolls adults with prostate, liver, or head and neck cancers who need radiation. Researchers w…

This study looks at the best timing for combining targeted radiation (SBRT) with hormone therapy in men whose prostate cancer has returned and spread. It also tests if radiation to the pelvis can stop cancer from spreading further. About 532 men with recurrent, hormone-sensitive …

This trial investigates whether adding the hormone therapy apalutamide to high-precision radiation (SBRT) can drive prostate-specific antigen (PSA) levels extremely low in men with intermediate-risk prostate cancer. Participants receive apalutamide to block testosterone that fuel…

This phase II trial is testing whether terbinafine, a widely used antifungal pill, can slow the rise of PSA in men whose prostate cancer has returned after initial treatment. The goal is to see if this well-tolerated drug can delay or replace standard hormone therapy, which often…

This phase 3 trial is testing whether adding the chemotherapy drug docetaxel to standard hormone therapy (ADT plus an ARPI) can lower the chance of prostate cancer growing or spreading. The study enrolls 830 men with metastatic prostate cancer that is sensitive to hormone therapy…

This trial tests a specialized radiation technique called SIB-VMAT for men with high-risk or very high-risk localized prostate cancer. The approach delivers a higher radiation dose to the tumor while giving a standard dose to nearby lymph nodes, all in 20 sessions over four weeks…

This early-stage trial tests a new drug called KTX-2001, alone or with another drug (darolutamide), in men with metastatic castration-resistant prostate cancer that has spread and stopped responding to hormone therapy. The main goals are to check safety, find the right dose, and …

This study tests a three-part program to increase the use of precision oncology—genetic testing that guides personalized treatment—for veterans with advanced lung or prostate cancer. The program includes a patient education video, feedback to doctors on their testing patterns, an…

This study is testing a new type of radiation therapy that adapts to changes in the prostate and bladder during each treatment session. It is for men with localized prostate cancer who also have an enlarged prostate or urinary symptoms. The goal is to see if this approach can red…

This study tests a new robot-assisted surgery for localized prostate cancer that leaves the full length of the urethra intact. The goal is to help men regain urinary continence faster after prostate removal. About 60 men with early-stage prostate cancer will undergo the procedure…

This study compares two radiotherapy schedules for men whose prostate cancer has returned after surgery. The standard treatment takes 5 weeks, while the shorter one takes 4 weeks. Researchers want to see if the shorter schedule causes no more side effects and controls the cancer …

This study tests whether adding targeted radiation or heat-based ablation to ongoing drug therapy can control genitourinary cancers (prostate, bladder, or kidney) that have started growing in only a few new areas. Participants continue their current systemic treatment while recei…

This study tests a personalized approach to radiation therapy for men whose prostate cancer has returned after surgery. Instead of giving everyone the same treatment, doctors will adjust the plan based on how well the cancer responds to initial radiation. Those who respond well m…

This study tests a high-dose radiation implant (brachytherapy) for men whose prostate cancer returned after standard external beam radiation. About 30 participants will receive this targeted treatment to the exact spot of recurrence, identified by advanced MRI. The goal is to con…

This phase 2 trial tests whether giving prostate cancer radiation in just 2 sessions is as safe and effective as the standard 5-session approach. About 100 men with low- or intermediate-risk prostate cancer will be randomly assigned to one of the two schedules. Both groups will u…

This early-stage trial tests a new treatment made from a patient's own immune cells (TILs) for metastatic colorectal or prostate cancer. The goal is to see if repeated doses are safe and feasible in 12 participants. The therapy aims to help the immune system fight cancer, but ong…

This Phase 3 trial tests whether adding the chemotherapy drug docetaxel to the standard treatment (apalutamide plus hormone therapy) can help men with metastatic hormone-sensitive prostate cancer who did not have a strong initial response to apalutamide alone. About 320 men will …

This Phase 3 trial is testing whether adding pelvic radiotherapy to standard hormone therapy can delay cancer progression in men whose prostate cancer has spread to nearby lymph nodes after prostate removal surgery. About 372 participants will be randomly assigned to receive eith…

This study tests whether giving radiation to the para-aortic lymph nodes (located in the abdomen) can better control prostate cancer that has returned in a limited number of spots. Men with hormone-sensitive prostate cancer and up to five lesions seen on a PSMA PET/CT scan will r…

This study is testing a new type of radiation therapy for early-stage prostate cancer that delivers very high doses in just a few sessions. The radiation machine adjusts the beam daily based on the patient's anatomy, aiming to protect healthy tissue. Researchers will track qualit…

This early-stage study tests a new treatment called ETB-DualNK-01 for men with advanced prostate cancer that has stopped responding to hormone therapy. The treatment uses donor immune cells (NK cells) that are engineered to target two cancer markers, PSMA and PSCA. The study aims…

This study tests a procedure called irreversible electroporation (IRE) using the NanoKnife system to treat intermediate-risk prostate cancer. The goal is to destroy cancer cells with fewer side effects than standard treatments like surgery or radiation. About 100 men over age 50 …

This study is testing a new way to give radiation for high-risk prostate cancer that has not spread. One hundred men will receive a shorter, stronger radiation boost to the prostate along with standard pelvic radiation. The goal is to see if this approach is safe and does not cau…

This study tests two drugs, cabozantinib and atezolizumab, in 33 men with a type of advanced prostate cancer that has spread and no longer responds to hormone therapy. The goal is to see if the combination can stop or shrink tumors. Participants must have non-measurable disease o…

This study follows 700 adults with prostate cancer who have already received at least one dose of lutetium-177 PSMA-617 in earlier Novartis trials. Researchers will monitor long-term side effects such as dry mouth, eye dryness, bone marrow problems, kidney damage, and new cancers…

This study tests a laser treatment guided by MRI to destroy early-stage prostate cancer in men aged 40-80 with low to intermediate risk. The goal is to control the cancer and avoid more aggressive treatments like surgery or radiation. Researchers will check results with follow-up…

This study looks at whether metformin, a drug used for diabetes, can help prostate cancer patients who have high blood sugar or are overweight. About 100 men will either take metformin plus get lifestyle advice, or just get lifestyle advice. The main goal is to see if it's possib…

This study tests whether taking creatine supplements along with a home-based resistance training program can help men with metastatic prostate cancer maintain muscle mass and reduce fatigue. Two hundred participants will be randomly assigned to receive either creatine or a placeb…

This trial is testing whether combining the drug Pluvicto with precise radiation (SBRT) can lower the chance of cancer returning in men with locally advanced prostate cancer, while also reducing the need for long-term hormone therapy. About 45 participants will receive one to thr…

This study tests an experimental drug called AAA817 in adults with a specific type of advanced prostate cancer (PSMA-positive) that has worsened after prior treatments, including a targeted therapy. About 443 participants will be randomly assigned to receive either AAA817 or the …

This study tests a precise radiation treatment (MR-guided high-dose-rate brachytherapy) for men whose prostate cancer has returned in the prostate bed after previous radiotherapy. About 20 participants will receive this targeted therapy to see if it can control the cancer with ac…

This study tests a mix of five oral drugs (hydroxychloroquine, metformin, sirolimus, dasatinib, and nelfinavir) in people with advanced solid tumors or prostate cancer that has come back. The goal is to find the safest dose and see if the combination can stop the cancer from grow…

This study looks at men with high-risk prostate cancer that appears on only one side of the prostate. During robotic surgery to remove the prostate, doctors will either remove lymph nodes from both sides of the pelvis or just the side with cancer. The goal is to see if removing f…

This study compares a shorter, high-dose radiation treatment (SBRT) to standard radiation for men whose prostate cancer has come back after surgery. About 284 men will be randomly assigned to one of the two approaches. The goal is to see if SBRT is as safe and effective, with few…

This study tests an internet-based program called iLIVE that combines weight loss coaching and online exercise classes for men who have had hormone therapy for prostate cancer. The goal is to see if it can reduce obesity and frailty, which are common side effects of treatment. Re…

This study tests whether a single, very high dose of precisely targeted radiation can safely treat intermediate-risk prostate cancer. About 200 men will receive one 24-Gy dose to the prostate, with a possible extra boost to the main tumor. Researchers will monitor side effects, q…

This trial tests a new injectable radioactive drug, Actinium-225 rhPSMA-10.1, in 60 men with advanced prostate cancer that has spread and stopped responding to other treatments. The drug is designed to attach to prostate cancer cells and destroy them with radiation. The study aim…

This phase 3 trial is testing whether taking aspirin and atorvastatin (a common cholesterol-lowering drug) can help men with castrate-resistant prostate cancer live longer. The study plans to enroll 1210 participants who are starting their first treatment for this advanced stage.…

This study tests if axelopran, a drug used for opioid-induced constipation, can slow tumor growth in people with advanced breast, lung, pancreas, or prostate cancer. About 34 adults whose cancer has worsened after standard treatment will take axelopran daily for up to a year. Res…

This study tests whether combining an experimental immunotherapy drug (SHR-1701) with targeted radiation can help men with metastatic castration-resistant prostate cancer, a form that no longer responds to hormone therapy. About 66 participants will receive either the drug plus r…

This study tests a new type of radiation therapy for men with high-risk prostate cancer that hasn't spread. The treatment uses advanced imaging to deliver higher radiation doses directly to the main tumor while also treating the whole pelvis. Researchers want to see if this appro…

This study is testing a new, shorter radiation treatment for men with early-stage prostate cancer. Instead of the usual 5 sessions, doctors will give 3 high-dose radiation treatments. The goal is to see if this approach is safe and causes fewer side effects while still controllin…

This phase 2 trial tests whether giving testosterone injections (bipolar androgen therapy) can delay the time it takes for prostate cancer to spread in men whose cancer is progressing despite standard treatment. About 69 men with non-metastatic castrate-resistant prostate cancer …

This study compares a standard robot-assisted prostate removal surgery to a newer, pelvic fascia-sparing approach that aims to preserve nerves and support structures. Researchers will enroll 600 men with localized prostate cancer to see if the new technique offers similar cancer …

This study is for men with a type of advanced prostate cancer that no longer responds to hormone therapy and has certain DNA repair gene changes. The trial compares the usual chemo (docetaxel) alone versus docetaxel plus a platinum chemo drug to see if the combination helps patie…

This phase 3 trial is testing whether a shorter, more intense radiation treatment called SBRT works as well as the current standard of external radiation plus a brachytherapy boost for men with unfavorable-risk prostate cancer. About 710 participants will also receive hormone the…

This phase 2 trial tests Enhertu, a targeted drug, in 60 men with HER2-positive prostate cancer that has spread and stopped responding to hormone therapy and newer drugs like abiraterone. Participants must have tried or refused chemotherapy. The study measures tumor shrinkage and…

This study tests whether adding omeprazole (a common heartburn medicine) to standard chemotherapy can help control advanced prostate cancer that has stopped responding to other treatments. About 50 men with castration-resistant prostate cancer will receive either omeprazole plus …

This early-phase trial is testing a new approach to CAR-T cell therapy for adults with advanced solid tumors that have not responded to standard treatments. The therapy uses a patient's own immune cells, engineered to recognize two cancer-specific targets chosen based on each per…

This study looks at whether proton therapy can safely treat cancers that return after standard radiation. Proton beams are more targeted than traditional X-rays, so they may deliver stronger doses to the tumor while sparing healthy tissue. Researchers will track side effects and …

This study compares two treatments for men with intermediate-risk prostate cancer: focal HIFU (a targeted ultrasound that destroys only the tumor) and radical prostatectomy (complete removal of the prostate). The goal is to see which approach offers better value for money and qua…

This study for veterans with prostate cancer that has returned in a few spots (oligorecurrence) compares standard systemic therapy alone versus standard therapy plus PET-directed local treatment using surgery or radiation. The goal is to see if adding local therapy delays the can…

This study follows 170 men in China with metastatic prostate cancer who are receiving a radioactive drug called lutetium-177. Researchers will track how much their PSA levels drop, how long the cancer stays controlled, and their quality of life during and up to one year after tre…

This early-stage trial is testing a new daily oral medication called ETX-19477 in about 120 adults with advanced solid tumors, including breast, ovarian, prostate, and other cancers. The drug blocks a protein called PARG to interfere with cancer cells' ability to repair themselve…

This study tests a smarter way to give radiation to men whose prostate cancer has come back after surgery. Using advanced scans, doctors will give higher radiation doses to the spots where cancer is active and lower doses to healthy areas. The goal is to control the cancer while …

This trial tests whether giving radiation every other day (5 sessions total) is as safe as the standard daily schedule (20 sessions) for men who have had prostate cancer surgery. The study involves 204 participants across multiple centers. The main goal is to see if the shorter s…

This early-stage trial tests a new oral drug called (R)-9bMS in about 18-30 men with metastatic castration-resistant prostate cancer, a form of prostate cancer that has stopped responding to hormone therapy. The drug works by blocking a protein called ACK1, which may help shrink …

The THUNDER trial is testing whether using advanced PET scans and a genetic test (Decipher) can help doctors choose the right treatment for high-risk prostate cancer. About 493 men will either get stronger treatment if their scans or genetic score show high risk, or less intense …

This study tests a new drug, KESONOTIDE™, in people with advanced solid tumors like prostate, breast, lung, ovarian, brain, pancreas, or skin cancer. The trial has two phases: first, finding the safest dose, then testing that dose in a larger group. About 80 participants will be …

This study is testing a new, shorter way to treat prostate cancer using proton therapy. Instead of the usual 5 sessions, researchers want to see if just 2 sessions are as safe and effective. The goal is to make treatment faster and more affordable while keeping side effects low. …

This study compares two types of radiation therapy (proton vs. photon) given after prostate removal surgery. The goal is to see if proton therapy causes fewer bowel problems and improves quality of life. About 900 men with prostate cancer will be randomly assigned to one of the t…

This study tests a surgical technique that grafts nerves to help men who have had lasting erectile dysfunction (ED) for over 18 months after prostate cancer surgery. About 100 men will receive the procedure and be followed for one year to see if their erections improve and if the…

This study tests a precise type of radiation therapy (MRgRT) that aims to protect the nerves and blood vessels needed for erections in 70 men with low- or intermediate-risk prostate cancer. Participants receive 5 high-dose radiation sessions guided by MRI. The goal is to see if t…

This study tests a new treatment called AZD0754 for men with metastatic prostate cancer that has spread and is no longer responding to hormone therapy. AZD0754 is a type of immunotherapy where a patient's own immune cells are modified in a lab to better recognize and attack cance…

This study tests whether a compound from licorice root, called glycyrrhizin, can reduce PSA levels in men with prostate cancer before they have surgery to remove the prostate. About 60 men who are scheduled for prostate removal will take glycyrrhizin daily for a short time. The g…

This study tests a new approach using immune cells from healthy donors, engineered to recognize and attack cancer cells. The target is chosen based on each participant's tumor profile. The trial includes 85 adults with advanced solid tumors that have not responded to standard tre…

This study tests a new drug called MBRC-201 in people with advanced solid tumors (prostate, breast, colorectal, lung, or pancreatic cancer) that have not responded to standard treatments. The drug is an antibody-drug conjugate, designed to deliver a cancer-killing agent directly …

This study tests a new treatment called EBNK-001, made from donor immune cells (natural killer cells), in people with advanced solid tumors that have not responded to standard therapies. Participants receive the cells after chemotherapy to prepare the body, along with low-dose in…

This early-phase study tests a new drug called ASP5541 in Chinese men with advanced prostate cancer. The drug is given as a shot in the hip, along with standard treatments prednisone and hormone therapy. The main goals are to check the drug's safety and how it is processed by the…

This study is testing whether a single, high-dose radiotherapy session can safely control prostate cancer in men with intermediate or high-risk disease. About 58 participants will receive one focused radiation dose to the tumor, guided by MRI and imaging. The goal is to see if th…

This early-phase trial is testing a new drug called CLSP-1025 in about 90 adults with advanced solid tumors (like lung, colon, or breast cancer) that have a specific p53 mutation (R175H). The drug works by directing the body's immune cells to attack cancer cells carrying this mut…

This phase 3 trial tests whether treating 1 to 10 metastatic tumors right away with precise radiation improves survival compared to waiting 3 months. It includes 800 adults with lung, colorectal, or prostate cancer that has spread to a few spots. Participants are randomly assigne…

This study tests a single, very high dose of radiation (17 Gy) to the prostate area in men whose prostate cancer has come back after surgery. The goal is to see if this precise, one-time treatment can control the cancer while reducing side effects. Fifty men will be enrolled, and…

This phase II trial is testing whether using a special PET/MR scan (PSMA) to guide radiation therapy can improve outcomes for men with high-risk prostate cancer. Fifty participants will receive targeted radiation boosts to areas identified by the scan. The main goal is to see if …

This study tests a new drug called OM-RCA-01, an antibody that blocks a protein called FGFR1 found on some cancer cells. About 58 adults with metastatic kidney, lung, prostate, breast, or head and neck cancers that express FGFR1 will receive the drug by IV every two weeks. The go…

This trial is testing two improvements to standard radiation therapy for men with high-risk prostate cancer. First, it adds a higher radiation dose (a boost) directly to the visible tumor inside the prostate, aiming to reduce the chance of cancer spreading. Second, it compares gi…

This study is testing a new way to deliver radiation for prostate cancer that adapts to daily changes in the body. It involves 100 men with low- or intermediate-risk prostate cancer. The goal is to see if this approach can better protect nearby organs and improve quality of life.

This study tests a new, less invasive way to treat intermediate-risk prostate cancer using a laser guided by micro-ultrasound. The goal is to see if the procedure is safe and can delay or avoid the need for more aggressive treatments like surgery or radiation. Seven men aged 40-8…

This phase III trial tests whether high-dose vitamin D can prevent bone loss in older men with prostate cancer who are receiving hormone therapy (ADT). The study will enroll 240 men aged 50 and older, giving them either high-dose vitamin D or a placebo for one year. Researchers w…

This study is testing whether giving only 3 doses of high-precision radiation (SBRT) over 3 days is as safe and effective as the usual 5-dose schedule for men with low or intermediate risk prostate cancer. The radiation is guided by a special catheter that acts like a GPS, tracki…

This study looks at men whose prostate cancer has returned after surgery, with new spots found on only one side of the pelvis using a special scan. The goal is to see if removing lymph nodes only on that one side works as well as removing them on both sides, while causing fewer s…

This study is testing a new way to deliver radiation for prostate and bladder cancers. The approach uses an MRI-guided machine to adapt the radiation dose in real time, giving a higher boost to the tumor while sparing nearby organs. Researchers want to see if this reduces side ef…

This study follows 130 men with metastatic prostate cancer who are receiving standard treatment with abiraterone and prednisone. Researchers want to see if a person's race or ethnicity influences how well the drugs work, by measuring PSA levels and looking at genetic differences.…

This study tests a new type of radiation therapy for prostate cancer that uses an MRI machine to guide the beam in real time. The goal is to deliver high doses of radiation more precisely to the tumor while sparing healthy tissue. The trial will enroll 50 men with localized or li…

This trial tests two drugs, trastuzumab and pertuzumab, already approved for breast cancer, in people with rare cancers that have a specific genetic change called HER2 amplification or mutation. About 30 adults and children with various rare or hard-to-treat cancers will receive …

This study tests whether men with low-volume metastatic prostate cancer can safely stop taking certain hormone drugs (apalutamide or enzalutamide) after 12 months, instead of continuing indefinitely. 400 men will be randomly assigned to either stop or continue therapy, with the o…

This phase II trial tests whether adding a radioactive drug called Lu-PSMA to precise radiation therapy can better control prostate cancer that has spread to just 1-3 spots. About 70 men with hormone-sensitive prostate cancer will be randomly assigned to get radiation alone or ra…

This study tests a program that helps prostate cancer patients become more physically active. It combines a personalized exercise plan, coaching from a fellow patient who is already active, and support from a doctor. The goal is to see if this approach helps men stay active long-…

This study tests whether a personalized diet and exercise program is practical for 30 men with metastatic prostate cancer who are already receiving hormone therapy. The goal is to see if patients can stick with the program and if it helps control their cancer. The study does not …

This study is testing a new type of radiation therapy called adaptive SBRT for men with intermediate- or favorable high-risk prostate cancer. The goal is to see if it can safely deliver a higher dose of radiation directly to the tumor while avoiding nearby organs, which may reduc…

This study is for people with a certain type of prostate cancer that is not too advanced but has some higher-risk features. It tests whether adding a short course of the drug darolutamide to standard radiation therapy can lower PSA levels to a very low target (0.1 ng/mL or less) …

This phase III trial tests whether adding radiation to the lymph nodes improves outcomes for men whose prostate cancer has returned after prostatectomy, indicated by a rising PSA. About 374 participants with low PSA levels will receive either standard radiation to the prostate be…

This study tests whether a very short course of radiation (5 days) is as safe and effective as a longer course (2-3 weeks) for men with localized prostate cancer. All participants also receive a brachytherapy boost. The main goal is to compare side effects and quality of life ove…

Researchers are testing a radioactive tracer called gallium-68 LNTH-2401 to see how well it works with PET/CT scans for finding prostate cancer in pelvic lymph nodes. The trial has two parts: first, they find the best dose and scan timing, then they check how accurately the scan …

This phase 2 trial is testing whether a special PET scan tracer called 18F-DCFPyL can accurately show how prostate cancer responds to standard radiation therapy. About 130 adults with newly diagnosed, localized prostate cancer will receive the tracer and undergo PET/CT scans at s…

After surgery to remove prostate cancer, cancer cells sometimes remain at the edge of the removed tissue, which can lead to the cancer returning. Researchers are testing a light-based imaging method called hyperspectral imaging to examine the removed prostate and identify cancer …

This study is testing whether a radioactive tracer called 18F-DCFPyL, used during a PET/CT scan, can better detect where prostate cancer has returned in men whose PSA levels are rising after initial treatment. About 350 men will be followed for up to 5 years with regular scans an…

This study tests a new PET/CT imaging agent called 68Ga-NYM032 in 232 men with suspected prostate cancer recurrence after initial treatment. Participants have rising PSA levels, and the scan aims to accurately locate any remaining cancer. The goal is to see how well the scan dete…

This phase 3 trial tests a new radioactive imaging agent, 64Cu-SAR-bisPSMA, to see if it can better detect prostate cancer that has spread to nearby lymph nodes. About 383 men with high-risk prostate cancer will receive a single injection of the agent before their scheduled prost…

This study tests whether a new type of ultrasound, called transperineal micro-ultrasound, can better detect prostate cancer during biopsy. Unlike standard ultrasound, this method uses higher frequency sound waves to create clearer images. Researchers will enroll 138 men scheduled…

Researchers are testing a device called the CARE phantom system to see if it can make prostate MRI measurements more consistent across different scanners. The study includes men aged 18 and older who are undergoing prostate cancer investigation and have suspicious lesions on MRI.…

This early study tests a new radioactive tracer called 68Ga-FC516 in 10 healthy adults and people with prostate cancer. The goal is to see if it is safe and how well it finds tumors on PET/CT scans compared to existing tracers. The results will help improve prostate cancer diagno…

This study tests whether a special PET scan using fluciclovine can help doctors decide on treatment for men whose prostate cancer has returned after initial treatment, but whose standard PSMA PET scan was unclear or negative. About 142 men will receive the fluciclovine PET scan, …

Researchers are testing whether a radioactive tracer called 68Ga/18F-PSMA/PSFA can improve PET/CT scans for finding tumors in people with PSMA-related cancers, including prostate and liver cancer. The study will enroll 500 adults with suspected, newly diagnosed, or previously tre…

Prostate biopsies can misjudge cancer severity up to 40% of the time. This trial tests a new needle that collects more tissue than standard ones, aiming to give pathologists a clearer sample. Researchers will compare tissue amount and quality from both needles in 200 men with sus…

This study is testing a blood test called Proclarix to see if it can better identify men with aggressive prostate cancer before they have a biopsy. About 500 men aged 40-75 with certain PSA levels will give a blood sample before their scheduled biopsy. The test results will be co…

This study tests whether taking multiple MRI scans before, during, and after standard radiation therapy can help doctors see how tumors change. Researchers will enroll people with advanced esophageal cancer, glioblastoma, prostate cancer, vulvar cancer, or pediatric glioma. The g…

This study is testing whether a new blood test can screen for many types of cancer at once. Researchers will enroll 24,000 adults aged 45-75 who do not have cancer. Participants will be randomly assigned to one of two blood test groups or a control group. The goal is to see how w…

This study compares a new artificial intelligence (AI) system to radiologists for reading prostate MRI scans to detect cancer. About 130 men who are already scheduled for a prostate biopsy will have their MRI read by both the AI and a radiologist. The goal is to see if the AI can…

This study tests a new software tool that automatically analyzes MRI images of the prostate to find cancer areas that doctors might miss. About 180 people with known or suspected prostate cancer will get an MRI and then a targeted biopsy. Researchers will compare the software's a…

This trial tests whether taking biopsy samples from only the side of the prostate where an MRI shows a suspicious lesion can match the standard approach of sampling both sides. Men with suspected prostate cancer and a single MRI lesion will be randomly assigned to receive either …

This study is testing a new blood test called PROSTest to see if it can accurately detect prostate cancer in men with high PSA levels. Researchers will compare the test results with standard prostate biopsy findings in 1,500 men. If the test works well, it could help many men avo…

This study enrolls 950 men with suspected but undiagnosed prostate cancer who are scheduled for a biopsy. Researchers will compare the accuracy of prostate MRI against a panel of blood and urine biomarkers (PCA3, PSA, TMPRSS2:ERG) in detecting clinically significant prostate canc…

This Phase 3 trial is testing whether combining a special PET scan (PSMA PET) with MRI can detect prostate cancer better than standard methods. About 204 men with suspected prostate cancer will receive the combined imaging, and results will be compared to biopsy findings. The goa…

This trial compares two ways of taking prostate tissue samples in men with suspicious MRI findings: through the rectum (transrectal) or through the skin between the scrotum and anus (transperineal). Both methods use MRI images to guide the biopsy needle. The main goal is to see i…

This study investigates whether a blood test (liquid biopsy) can detect prostate cancer early by looking for tumor cells and genetic material in the blood. Researchers will compare blood samples from men with suspected prostate cancer to those without the disease. The goal is to …

This early-stage study tests a new radioactive imaging agent called 68Ga-OncoACP3 in 20 men with prostate cancer. The goal is to see if it is safe and can help detect cancer that has spread or come back. Participants receive one injection and then undergo PET scans to measure rad…

This study tests a new imaging approach for people with advanced breast or prostate cancer. It uses two radioactive tracers to find tumors that have a specific protein (GRPR). The goal is to see if this method is safe and can help doctors see where the cancer is in the body. Abou…

This study tests whether combining two advanced imaging techniques (micro-ultrasound and MRI) during prostate biopsy can find more aggressive cancers than the current standard approach. About 400 men with suspected prostate cancer will participate. The goal is to improve detectio…

This study compares a newer PSMA PET scan to the standard MRI for staging prostate cancer in men eligible for focal therapy (treatment that targets only the tumor). About 138 men with early-stage prostate cancer will be randomly assigned to get the PSMA PET scan or not. The goal …

This phase 2 trial tests whether a radioactive tracer called 64Cu-DOTA-AE105 can accurately show the aggressiveness of prostate cancer on a PET scan. About 168 men with low- to intermediate-risk prostate cancer will receive the tracer and undergo imaging. The goal is to see if th…

This study tests a new microscope called LaserSAFE that scans the removed prostate during surgery to see if cancer cells are at the edge. If it works well, surgeons can decide right away whether to spare nearby nerves. About 693 men with prostate cancer will take part, and the st…

This study is testing whether a special type of PET/CT scan (PSMA-PET CT) can accurately detect aggressive prostate cancer in men who are on active surveillance (watchful waiting). Researchers will scan 200 men with low- or favorable intermediate-risk prostate cancer at the start…

This study tests two advanced imaging techniques, PSMA PET/CT and MRI-RSI, against the standard MRI to see which finds and outlines prostate tumors most accurately. Fifty men with newly diagnosed, higher-risk prostate cancer will undergo all scans and a targeted biopsy. The goal …

This study aims to develop a blood test that detects RNA from tiny particles (exosomes) to predict if prostate cancer has spread to the bones. Researchers will analyze blood samples from 1,000 men with newly diagnosed prostate cancer and compare results with PSMA PET scans. The g…

This study is testing whether taking a delayed PET/CT scan 2-3 hours after injection of a radioactive tracer can better detect aggressive prostate cancer compared to the standard 60-minute scan. Researchers will enroll 1,000 men with suspected prostate cancer who have not yet had…

This study tests a custom electrical impedance probe that measures tissue properties during prostate removal surgery. The goal is to see if it can instantly detect any cancer left behind, helping surgeons remove it all in one go. Two hundred men with prostate cancer will take par…

This study tests whether combining two types of scans (PET and MRI) before a prostate biopsy can more accurately find serious prostate cancers while avoiding unnecessary biopsies for low-risk cancers. About 167 men with suspected prostate cancer will receive the combined scan, an…

This study is testing whether a PSMA-PET scan using a radioactive tracer called 18F-rhPSMA-7.3 can accurately detect prostate cancer that has come back after focal gland treatment. About 70 men who had focal therapy for intermediate-risk prostate cancer will receive the scan, and…

This study tests a new way to decide who needs a prostate biopsy. Instead of relying only on MRI, it adds a blood test called Prostate Health Index (PHI) to better tell which men have dangerous prostate cancer. The goal is to safely skip biopsies in men with low-risk findings, re…

This study follows 100 men who have suspicious spots on prostate MRI but no significant cancer on their first biopsy. Over one year, they will have repeat MRI scans and biopsies to see if changes in those spots predict the development of clinically significant prostate cancer. Th…

This study is testing a blood test that looks for DNA signals from 20 different cancers, including lung, breast, and colon cancer. Researchers will see if the test can find cancer early, detect any cancer left after treatment, and catch a relapse before it shows up on scans. The …

This study tests a new way to do PET scans for men with high-risk prostate cancer. Instead of two full CT scans, it uses one CT plus a delayed PET-only image, which may lower radiation exposure. Researchers will check if the delayed images match the standard ones well enough. The…

This study compares two prostate biopsy techniques—cognitive-targeted and MRI-ultrasound fusion—to see which detects prostate cancer more accurately. About 80 men with elevated PSA and suspicious MRI findings will participate. Results may help doctors choose the best biopsy metho…

This study is testing a new AI-powered blood test that looks at platelets and immune cells to find early signs of eight different cancers, including lung, breast, and pancreatic cancer. Researchers will collect blood samples from 6,000 adults aged 40 and older, both with and with…

This study compares a new PET-CT scan (FCH-PET-CT) to standard imaging (bone scan and MRI/CT) to see which better finds cancer that has spread outside the pelvis in men with prostate cancer and specific DNA repair gene mutations. About 50 men with these mutations will be enrolled…

This study tests whether a special PET/MRI scan (PSMA) can find aggressive prostate cancer better than standard biopsies in men with a negative MRI but still suspected of having cancer. One hundred men will receive both the new targeted biopsies and standard systematic biopsies. …

This study tests a new strategy for diagnosing prostate cancer in men with moderate risk. Instead of immediately doing a biopsy, doctors will monitor them with regular PSA tests and MRI scans. The goal is to see if this approach can safely delay biopsies, avoid unnecessary proced…

This study is testing a new way to screen for aggressive prostate cancer. Researchers will give 1,500 men aged 40-69 a genetic risk score, a PSA blood test, and a special MRI. The goal is to see if combining genetic risk with MRI can better identify high-grade cancers that could …

This phase II trial is testing whether a special PET/CT scan using flotufolastat F 18 can accurately find prostate cancer that remains or returns after focal therapy (such as laser or freezing). The study will enroll 81 men who had focal therapy 6 to 36 months ago. If the scan wo…

This study tests a new FDA-approved device called the Histolog Scanner, which takes high-resolution images of the prostate surface right after it is removed during surgery. The goal is to see if this faster method can save more than 20 minutes compared to the standard lab process…

This study compares two ways to use MRI images during prostate biopsy: software fusion (computer-assisted) and cognitive fusion (doctor's visual estimate). Over 1,300 men with suspicious prostate lesions will be randomly assigned to one method. The goal is to see which technique …

This study tests a new way of reading PSMA PET/CT scans, called the Istanbul PSMA PET/CT Criteria, to see if it can better identify which men with low-risk prostate cancer can safely choose active surveillance (monitoring instead of immediate treatment). The researchers will enro…

This study tests a software tool called TRAQinform Theranostics that analyzes PET/CT scans to help doctors decide on treatment for metastatic prostate cancer. Researchers will see if having this extra information changes the treatment plan. The study involves 32 patients starting…

This study follows men who had a negative prostate cancer screening about five years ago. They will undergo a repeat MRI and PSA test to see if any clinically significant prostate cancers have developed. The goal is to learn whether repeat screening is valuable and how often it s…

This study tests whether cannabidiol (CBD) can reduce the need for strong painkillers (opioids) in people with end-stage prostate cancer that has spread and no longer responds to standard treatments. About 58 participants will receive either CBD or a placebo three times daily for…

This study looks at whether adding local anesthesia (numbing medicine) during a prostate biopsy, while patients are already sedated, reduces pain after the procedure. About 800 men will take part. The goal is to see if this simple change can lower pain scores, cut down on painkil…

This study tests a device called the Axonics SNM System, which uses mild electrical pulses to calm the nerves that control the bladder. It is for men with overactive bladder, including those with urgency incontinence or frequent urination. The trial will enroll 150 men and track …

This phase 2 trial tests whether a low dose of naltrexone (LDN) can reduce fatigue in men with prostate cancer who are on hormone therapy (ADT). The study will enroll 60 participants and measure fatigue, quality of life, and safety. It is not yet recruiting.

This study will compare how men with intermediate-risk prostate cancer feel about their quality of life after either total prostate removal (surgery) or a less invasive treatment called focal HIFU (high-intensity focused ultrasound). About 100 sexually active men aged 40-75 will …

This study tests a drug called fezolinetant to see if it can reduce hot flashes in men with prostate cancer who are on hormone therapy (androgen deprivation therapy). About 60 men will take either the drug or a placebo daily for 4 weeks. Researchers will track hot flash frequency…

This study tests whether a small device that sends mild electrical pulses through the skin (TENS) can reduce pain during a prostate biopsy. About 140 men will get either a real TENS device or a fake one, along with standard numbing medicine. The goal is to see if TENS makes the p…

This trial tests whether a digital program called E-Mergir can improve sexual and mental well-being in men who have survived prostate cancer. Many survivors face lasting sexual difficulties and emotional distress, yet few have access to tailored support. The program, delivered th…

This study tests whether cancer patients can complete a supervised exercise program from home using video calls. The program includes resistance training with dumbbells and aerobic exercise. Researchers want to see if this approach is practical and helps patients maintain functio…

This trial investigates whether a laser surgery called HoLEP, which removes excess prostate tissue to improve urinary symptoms, can improve quality of life when performed before radiation therapy in men with both prostate cancer and bothersome lower urinary tract symptoms. The st…

This study tests whether wearing a virtual reality (VR) headset during daily radiation therapy can help manage anxiety in people with prostate, breast, lung, or head and neck cancer. About 54 patients will use a Meta Quest 2 headset during their treatments, and researchers will t…

This study looks at whether a special low-field MRI scanner can give clearer images for prostate cancer radiation therapy in people who have both hips replaced. Standard MRI often creates blurry images around metal implants, making it hard to aim the radiation precisely. The rese…

This study tests whether taking omega-3 fish oil capsules and doing simple resistance exercises with elastic bands can help cancer patients maintain muscle mass and strength. It involves 288 adults with various cancers who are at risk of muscle wasting. The goal is to improve phy…

This study tests if a newer, more precise type of radiation (adaptive SBRT) can cause fewer urinary problems than standard radiation for men with localized prostate cancer. About 320 men will be randomly assigned to one of the two radiation methods. The goal is to see if the newe…

This study tests whether a supervised golf exercise program can improve physical function, mental health, and quality of life in prostate cancer survivors who are on hormone therapy. Twenty men aged 55-85 with little or no golf experience will participate. The program includes wa…

This study tests whether applying a powder called ARISTA AH during robotic prostate removal can reduce blood loss and help preserve erectile function. About 362 men with prostate cancer will be randomly assigned to receive the powder or standard care. The goal is to see if the po…

This study looks at whether men recovering from robotic prostate surgery can manage pain without automatically receiving opioid painkillers. Half of the 300 participants will get a standard pain plan plus an opioid prescription, while the other half will get only the pain plan an…

This study tests whether a high-protein nutrition plan combined with resistance exercises, started weeks before surgery and continued for 24 weeks after, can help older adults with cancer preserve their physical function. The trial enrolls Veterans aged 55 and older with certain …

This study looks at whether saving a small extra artery to the penis during robotic prostate cancer surgery can help men recover erections. About 1 in 3 men have this artery, and the study will use MRI scans to find it before surgery. Researchers will follow 20-40 men for a year …

This pilot study is testing a new way to give radiation for prostate cancer that uses an MRI machine to guide the treatment. The goal is to give a lower dose of radiation to the whole prostate while giving a higher dose only to the main tumor, which may reduce side effects like u…

This study tests whether a mobile app with educational videos, pelvic floor exercises, and reminders can improve recovery of bladder control and erectile function in men after prostate cancer surgery. About 78 men scheduled for prostate removal will be randomly assigned to either…

This study is testing whether giving a lower dose of radiation in just two sessions can reduce side effects for men with intermediate-risk prostate cancer. All participants will be treated on a special MRI-guided machine (MR-Linac) that adapts the radiation daily. The main goal i…

This study tests a program called PC-PEP in 400 men who have had prostate cancer. The program teaches life skills and healthy habits to reduce side effects like incontinence and sexual problems, and to improve mental health, fitness, and overall quality of life. Participants will…

This study tests a telehealth program called ENGAGE for people with stage IV breast, prostate, lung, or colorectal cancer. The program helps manage symptoms like pain, fatigue, and distress that interfere with daily life. About 190 participants will be randomly assigned to ENGAGE…

This study tests whether a 12-week home-based exercise program can improve heart and lung fitness in men with prostate cancer who are on hormone therapy (androgen deprivation therapy). Sixty men will either follow the exercise program or receive healthy living education. The goal…

This study looks at whether a 6-month home exercise and nutrition program can improve thinking and physical abilities in cancer survivors aged 65 and older, along with their support person. About 1,500 participants will be assigned to either a virtually supervised or unsupervised…

This trial tests whether a structured nurse-led education session before prostate cancer surgery, plus a direct referral to pelvic floor physiotherapy, can reduce urinary incontinence afterward. Eighty men having their prostate removed will be randomly assigned to either standard…

This study compares two types of radiation for prostate cancer: one that targets only the tumor and one that treats the whole prostate. The goal is to see if the focused approach causes fewer short-term side effects like bladder or bowel problems. About 150 men with intermediate-…

This study tests whether giving a lower radiation dose to healthy parts of the prostate, while keeping a high dose to visible tumors, can reduce bowel and urinary side effects in men with low or intermediate-risk prostate cancer. Participants will receive two sessions of MRI-guid…

This study tests a newer type of radiation therapy that adjusts to daily changes in a patient's body shape. The goal is to safely use smaller treatment areas to reduce side effects like bladder and bowel problems. About 280 adults with pelvic cancers (prostate, bladder, rectal, a…

This study tests a drug called fezolinetant, already approved for hot flashes in menopausal women, to see if it can reduce hot flashes in men with prostate cancer who are on hormone-lowering therapy. About 32 men will take the drug daily for 28 days. The goal is to measure how mu…

This study tests whether acupuncture can reduce hot flashes and improve quality of life in men receiving hormone therapy for prostate cancer. Twenty-four men will be randomly assigned to start acupuncture right away or after a delay, and all will receive standard lifestyle advice…

This study tests whether a digital support program can help people with breast, prostate, or colorectal cancer reduce the time they spend sitting during their treatment. The goal is to improve their well-being and lower future health risks. About 172 participants will use an acti…

This study tests whether a digital exercise program with online group sessions can help prostate cancer patients on hormone therapy exercise more regularly. 160 participants will either get standard care or standard care plus the digital program. Adherence is tracked with a weara…

This study tests whether adding neuromuscular electrical stimulation to a regular exercise program can help men on long-term hormone therapy for prostate cancer maintain leg muscle strength. About 48 participants will be assigned to either exercise alone or exercise plus electric…

This study tests a precise radiation technique called neurovascular-sparing SBRT for men with prostate cancer. The goal is to see if customizing each treatment session based on MRI images can better protect the nerves and blood vessels needed for erections, compared to standard r…

This pilot study is testing whether a web-based insomnia treatment called SHUTi can help Black/African American prostate cancer survivors sleep better. Forty participants will be randomly assigned to either the SHUTi program or an educational website. The study will check if the …

This study looks at whether daily text message reminders to do pelvic floor exercises can help men recover bladder control faster after prostate surgery. About 132 men who are planning to have prostate surgery will be split into two groups: one gets the text reminders, the other …

This study is testing a supervised exercise program for people with cancer. Participants will take part in group exercise classes twice a week for 8 to 12 weeks. The goal is to see if the program helps improve physical activity levels and manage cancer-related symptoms. The study…

This study tests a 12-week prehabilitation program for 20 prostate cancer patients about to start hormone and radiation therapy. The program includes physical exercise and a 4-day residential session with education and activities. Researchers want to see if patients and their fam…

This trial compares two different schedules of MRI-guided radiation for men with low or favorable intermediate risk prostate cancer. One group gets the standard five sessions, the other gets just two sessions. The goal is to see if the shorter course can maintain cancer control w…

This study is looking for substances in urine that could help predict how well prostate cancer treatments work. Researchers will collect urine samples from 360 men with prostate cancer who are receiving standard treatments like surgery, radiation, chemotherapy, or hormone therapy…

This study collects blood, urine, saliva, and tumor tissue from 3,000 men with prostate cancer to investigate genetic changes that cause the disease. Participants may also undergo imaging and answer quality-of-life questions. The goal is to better understand prostate cancer and l…

This study collects blood samples from 1,000 men with prostate cancer to look for genetic differences that might explain why some cancers stop responding to hormone therapy. Participants give blood at clinic visits, and researchers analyze DNA and other genetic material. No treat…

This study uses detailed MRI scans and targeted biopsies to investigate why some prostate cancers come back after radiation therapy. Researchers will follow 300 men who are scheduled for radiation or whose cancer has returned after earlier treatment. The goal is to better underst…

The PROMISE registry collects health information and saliva samples from people diagnosed with prostate cancer at any stage. Researchers test the samples for inherited gene variants that raise cancer risk and follow participants for at least 15 years. The goal is to learn how the…

This study is testing a new algorithm that uses a liquid biopsy (a simple blood test) to find HRR gene mutations in patients with metastatic prostate cancer. It is for patients whose tumor tissue is not available or is inadequate for standard testing. The goal is to see if this m…

This study looks at whether artificial intelligence (AI) can help radiologists find prostate cancer on MRI scans. About 150 men aged 55-80 who are scheduled for a prostate biopsy will take part. The AI software will be compared to radiologists reading the scans alone. The goal is…

This study is testing a new PET-CT scanner that takes high-resolution images of tissue removed during cancer surgery. Researchers want to see if these images match lab results and help surgeons make better decisions. The study will include 850 people with prostate, breast, head a…

This study is creating a large database of medical information and blood samples from 350 adults receiving metabolic radiotherapy for thyroid, prostate, or neuroendocrine cancers. The goal is to provide researchers with valuable data to better understand these treatments. No new …

Researchers at University Hospital, Strasbourg, are developing 3D tumor models grown from patient tissue to study kidney, bladder, and prostate cancers. The study collects tumor samples and a small blood sample from about 100 adults with these cancers. Scientists use the blood to…

This study is testing whether two types of PET scans can better detect where prostate cancer has spread in the body. About 300 men with prostate cancer that is getting worse will receive injections of a radioactive tracer and then be scanned. The goal is to see if these scans are…

This study will follow 700 men with high-risk localized or metastatic prostate cancer to collect detailed information on how they are treated in everyday practice. Researchers will track treatments, side effects, quality of life, and disease progression over time. The goal is to …

This study looks at how the head-down position and gas used during robotic prostate surgery affect pressure inside the eye. Researchers will measure eye pressure with a simple ultrasound in 50 men having either robotic or open prostate surgery. The goal is to understand these cha…

This study is gathering medical records and imaging data from 10,000 men with prostate cancer or at high risk. Researchers aim to find patterns in scans that could help diagnose and treat the disease more effectively. No new drugs or procedures are being tested.

This study is collecting blood, urine, tissue samples, and health information from 300 men with advanced prostate cancer. Researchers hope to build a resource that will help them learn more about the disease and improve future care. Participants will not receive any experimental …

This study tracks 500 men aged 30-75 who have specific genetic changes linked to prostate cancer but have not been diagnosed. Researchers will monitor their health over time using yearly exams, blood tests, and MRI scans to understand how these genes affect cancer risk. The goal …

This study compares two levels of patient navigation—high-intensity versus low-intensity—to see which helps more people with prostate or kidney cancer enroll in clinical trials. About 90 participants will be randomly assigned to receive either extra support from a patient navigat…

This study collects blood and tissue samples from 2000 people—some with cancer and some without—to create a blinded reference set. Researchers will use these samples to evaluate how well new blood tests can detect many types of cancer early. The goal is to improve the accuracy of…

This study follows 3,000 men with early-stage prostate cancer who have chosen active surveillance (close monitoring instead of immediate treatment). The goal is to discover biological markers that can tell apart aggressive cancers from slow-growing ones. Researchers hope this wil…

This study uses special PET/CT scans to see how advanced prostate cancer becomes resistant to newer hormone therapies like enzalutamide or abiraterone. Researchers will track changes in cancer lesions over time in 25 participants. The goal is to better understand resistance patte…

This study collects blood and other biospecimens from adults with cancer to analyze immune-suppressing cells and genetic changes. Up to 1,750 participants will provide samples before and after chemotherapy. The goal is to better understand how cancer affects the immune system, bu…

This study collects blood or cheek swab samples from 1,100 cancer patients at the National Cancer Institute to analyze genetic differences that may influence how their bodies process cancer treatments. The goal is to understand why some patients experience more side effects or le…

This study tracks 270 men with metastatic hormone-sensitive prostate cancer to see how faithfully they take their apalutamide pills over the first year. Researchers will use questionnaires to measure adherence and identify who is at risk of skipping doses. The goal is to learn wh…

This study collects blood, urine, saliva, and tissue samples from nearly 6,000 people who have or may have cancer, including rare inherited forms. The samples are stored and used for research to understand the genetic and molecular basis of cancer. No new treatment is being teste…

This study explores whether artificial intelligence, combined with large-scale healthcare records, can help personalize radiotherapy for prostate cancer. By analyzing data from 15,000 patients, researchers aim to find ways to reduce damage to healthy tissue without compromising t…

This study observes 400 men in Russia with aggressive, high-volume metastatic hormone-sensitive prostate cancer. Researchers will track which treatments doctors use (like hormone therapy, chemotherapy, or radiation) and test blood samples for genetic mutations. The goal is to und…

This research project tracks men treated with a technology called High-Intensity Focused Ultrasound (HIFU) for prostate cancer or an enlarged prostate. The goal is to see how well this treatment controls disease and affects urinary and sexual function over 10 to 20 years. By coll…

This study follows 106 men who have had surgery for prostate cancer to see how well they recover bladder control, sexual function, and overall health. Participants will receive standard care plus optional exercise programs. The goal is to better understand recovery timelines and …

This study looks at how a man's age, health conditions like diabetes or high blood pressure, and sexual function before surgery affect the return of erections after nerve-sparing robotic prostatectomy for prostate cancer. Researchers will track 300 patients for a year, collecting…

This study explores how patients and healthcare providers view the use of genetic risk profiling for prostate cancer in everyday clinical practice. Through interviews, researchers aim to understand the benefits, challenges, and needs associated with receiving and delivering genet…

This study looks at why some older adults with serious conditions like cancer or fractures become vulnerable or frail. Researchers will follow about 1500 patients to find out how common different causes of vulnerability are and how they affect outcomes like survival and quality o…

This trial asks whether five advanced AI models can match the treatment recommendations of expert tumor boards for cancer patients. Using 100 standardized synthetic cases across breast, lung, urological, digestive, and gynecological cancers, each AI and two independent tumor boar…

This study follows 320 men with prostate cancer who receive a hydrogel spacer (SpaceOAR) before radiotherapy. The spacer is placed between the prostate and rectum to protect healthy tissue. Researchers will collect data from medical records and patient questionnaires over three y…

This study tests whether a new online tool, called BeSpoke, helps men with newly diagnosed localized prostate cancer make better treatment decisions. The tool gives personalized information about different treatments and their likely outcomes. Researchers will compare men who use…

This pilot study tests whether a new type of CT scanner, called photon-counting CT, can clearly show the urethra in prostate cancer patients without inserting a catheter. Currently, catheters are often needed to see the urethra during radiotherapy planning, which can be uncomfort…

This study tests whether a large language model (a type of AI) can accurately stage prostate cancer by reading Chinese PSMA PET/CT reports. Researchers will compare the AI's staging against expert doctors' assessments using thousands of de-identified reports. The goal is to see i…

This study aims to create and improve educational materials about genetic testing for cancer patients from diverse backgrounds. Researchers will interview 445 people with breast, ovarian, pancreatic, prostate, or colorectal cancer who speak English, Spanish, or Haitian Creole. Th…

This study is not testing a new drug but rather observing how darolutamide is actually used in everyday urology clinics for men with metastatic hormone-sensitive prostate cancer. Researchers will review medical records of about 1,400 patients to understand who gets which treatmen…

This study follows 700 men with prostate cancer that has spread to up to 10 spots in the body (oligometastatic). All receive radiotherapy to the prostate and to each visible metastasis, along with standard systemic therapy. Researchers collect real-world data from medical records…

This study is building a huge registry of information and biological samples from adults with or at risk for many types of cancer, as well as healthy volunteers. Researchers will use this resource to study what causes cancer and how to better prevent, detect, and treat it. The re…

This study is collecting detailed genetic and health information from 500 people with various cancers, including breast, lung, and leukemia. The goal is to create a shared database that helps researchers develop more personalized treatments. Participants provide samples and data,…

This registry gathers real-world information from thousands of men treated with high-intensity focused ultrasound (HIFU) for prostate cancer using the Focal One device. The goal is to monitor safety and track cancer control through routine PSA tests and MRI scans. By collecting d…

This study tests whether a questionnaire can help doctors spot side effects early in people who have finished treatment for breast or prostate cancer. About 200 survivors will either use the questionnaire or receive standard care. The goal is to see if active monitoring improves …

This study looks at whether men with prostate cancer who have hot flashes from hormone therapy will consistently wear a smartwatch to track their symptoms. For 4 weeks, 18 participants will wear the watch, log hot flashes by pressing a button, and complete daily surveys. The goal…

This study is figuring out what normal PSA levels are for trans women and non-binary people who have a prostate. Researchers will measure PSA in 500 volunteers aged 40 and older who are on hormones or have had lower surgery. The goal is to help doctors better detect prostate canc…

This study is testing whether a new genetic test (called PCAI ImmunoScore) can predict how well men with high-risk prostate cancer will respond to the drug darolutamide before surgery. About 100 participants will take darolutamide for 3-4 months, then have their prostate removed.…

This study is for men with intermediate- or high-risk prostate cancer who will receive hormone therapy and radiation. Researchers want to see if using a special PET scan (PSMA PET) during hormone therapy can help doctors better target remaining cancer with radiation while avoidin…

This study compares three different blood tests (CellSearch, Parsortix, and SmartCatch) to see which one best detects circulating tumor cells in patients with metastatic breast or prostate cancer. Researchers will take blood samples from 54 patients before they start a new treatm…

This study follows men with low-risk prostate cancer who have chosen active surveillance—monitoring the cancer over time rather than treating it right away. Researchers will collect data for years to learn which signs predict that the cancer may become aggressive. The goal is to …

This study is a large international registry that will follow at least 5,000 men with advanced prostate cancer for five years or more. Researchers will collect detailed information on treatments, side effects, and quality of life to see which approaches work best. The goal is to …

This study is testing whether an 8-minute educational video can effectively prepare cancer patients for genetic testing, compared to standard genetic counseling. Over 1,000 adults with various cancers will participate. The goal is to see if the video is acceptable and improves un…

This study follows 837 men with high-risk prostate cancer who choose either robot-assisted surgery or radiation therapy (with or without hormone therapy). Researchers will compare quality of life, side effects, and cancer control over time. The goal is to help patients and doctor…

This study is developing an AI system that tracks tumors and organs during radiation therapy without needing physical markers. Researchers will use existing patient data to train and test the AI. If it works, it could help doctors target radiation more accurately. The study invol…

This study aims to validate a gene test that identifies oxygen-starved (hypoxic) tumours in bladder and prostate cancer patients. About 30 participants will provide tumour samples and blood, and some will have MRI scans. The goal is to see if this test can help doctors choose mor…

This study is for people with advanced cancers who are taking long-term targeted treatments. Researchers want to learn about their experiences through interviews. The goal is to find better ways to support these patients. The study is currently recruiting 75 participants.

This study looks at whether exposure to chlordecone, a pesticide banned in 1993 but still present in the environment, is linked to prostate cancer in men from Martinique. Researchers will compare 3600 men with and without prostate cancer, measuring chlordecone levels in blood and…

This study follows 102 men with metastatic hormone-sensitive prostate cancer who are taking standard drugs (abiraterone, apalutamide, enzalutamide, or darolutamide) plus hormone therapy. Researchers will check thinking skills, fatigue, mood, and sleep at the start, 3 months, and …

This study interviews 24 men with prostate cancer to learn how they feel about breast-related side effects, such as gynecomastia (enlarged breasts), from treatment. The goal is to understand what matters most to patients when choosing therapies. Results will help design a future …

This study is testing whether a special type of scan called PSMA PET can better monitor how prostate cancer responds to treatment. Researchers will scan 110 men with high-risk prostate cancer before and after treatment to see if changes in the scan match standard measures like PS…

This study compares three surgical methods for removing the prostate in men with prostate cancer: robot-assisted laparoscopy, standard laparoscopy, and open surgery. Researchers will track urinary and erectile function before and after surgery in 2,000 participants. The goal is t…

This study uses online surveys to learn about the real-life experiences of people diagnosed with cancer and their caregivers. Researchers want to understand the emotional, physical, social, and financial challenges they face. The goal is to use this information to improve support…

This study aims to improve treatment for aggressive prostate cancer by growing 3D mini-tumors from patient samples in the lab. Researchers will compare two techniques to see which better predicts how a patient's cancer will respond to radiation or drugs. The goal is to help docto…

This study aims to describe the characteristics of prostate cancer in Algeria, including patient demographics, symptoms, diagnosis methods, and treatments. Researchers will collect data from 2,000 men aged 19 and older with confirmed prostate cancer. The goal is to better underst…

This study follows 500 men who had their prostate removed for cancer. Researchers check PSA levels soon after surgery to see if they can predict if the cancer will come back or spread. No new treatments are given—just standard care and observation.

This study follows 64 men with localized prostate cancer who undergo laparoscopic radical prostatectomy (keyhole surgery to remove the prostate). The goal is to track any complications that occur from the day of surgery up to 30 days later. By understanding how often problems hap…

This study looks at how SPECT imaging can help doctors measure the amount of radiation reaching healthy organs during certain cancer treatments. About 80 adults with advanced prostate or other cancers will get extra SPECT scans before and after their standard radiation therapy. T…

This study compares regular MRI scans to standard care for men with low- to medium-risk prostate cancer who choose active surveillance (monitoring instead of immediate treatment). The goal is to see if MRIs can detect cancer progression earlier and more accurately, potentially re…

This study aims to see if specially trained radiographers can make decisions about prostate MRI scans as well as radiologists. The goal is to reduce the need for contrast injections and extra scans, making care faster and more efficient. The study will involve 1600 patients and c…

This study is testing whether a special type of PET scan (PSMA PET) can predict how prostate cancer will progress in people who are newly diagnosed and have not yet had any treatment. Researchers will follow 1000 participants for at least 2 years to see if the scan results can fo…

This study compares two ways to check men with high PSA levels for dangerous prostate cancer: giving everyone an MRI first, or using a risk calculator to decide who needs an MRI and biopsy. The goal is to see if the calculator method catches just as many serious cancers while red…

This study is a registry that will follow about 5,000 men with prostate cancer that has come back or spread. It aims to record which treatments doctors actually use in routine care and how the disease progresses over time. Participants are grouped by their cancer stage, from PSA …

This study is collecting blood samples and imaging scans from 144 prostate cancer patients before, during, and after standard radiation therapy. Researchers want to see if changes in circulating tumor cells and MRI/PET imaging features can help predict how well the cancer respond…

This study is a large registry that will follow about 8,000 cancer patients who receive radiation therapy using a special machine called an MR-Linac, which combines an MRI scanner with a radiation beam. The goal is to learn how well this technology works for different cancers, in…

This study is creating a large registry of 1,500 men with newly diagnosed prostate cancer. Researchers will track their health, side effects, and quality of life over time to better understand how different treatments affect patients. The goal is to build a platform for future st…

This study looks at how urological diseases and their treatments impact patients' work life. Researchers will survey 2,000 adults admitted to a hospital in Poland, focusing on those having major cancer surgeries or stone procedures. Participants will be followed for 6 months to t…

This study looks at whether a person's inherited genetic risk can predict if they have prostate cancer. Researchers will compare the genetic risk scores of 1,000 men aged 40-69 who are already scheduled for a prostate biopsy. The goal is to see if men with higher genetic risk are…

This study looks at whether PSMA PET scans can predict how well advanced prostate cancer patients will respond to treatments like hormone therapy or chemotherapy. Researchers will scan 1300 patients before they start treatment and track their outcomes. The goal is to find imaging…

This study is testing whether educational videos and brochures can help Spanish-speaking Latinx patients with breast or prostate cancer better understand their radiation therapy and clinical trials. About 194 participants will watch videos or read brochures, then answer questions…

This study looks at whether having a pharmacist review all medications (including those from other doctors) can improve safety for cancer patients receiving targeted radionuclide therapy. The study will include 600 adults with thyroid cancer, metastatic prostate cancer, or neuroe…

This study looks at two methods of monitoring blood pressure during robot-assisted prostate removal surgery. The goal is to see if using a standard arm cuff (oscillometric) is as good as using a small tube in an artery (intraarterial) at preventing dangerously low blood pressure …

This study follows 200 men with low-risk prostate cancer who are on active surveillance (monitoring instead of immediate treatment). Researchers want to see if men with a higher genetic risk for prostate cancer are more likely to have their cancer progress over time. The goal is …

This study looks at how a type of radiation called HDR brachytherapy changes prostate cancer on a molecular level. Researchers will analyze blood, tissue, and gut bacteria samples from 100 men with low-risk or early intermediate-risk prostate cancer. The goal is to find the best …

This study is testing whether dried blood spots from a finger prick can reliably measure levels of common prostate cancer drugs. Researchers will compare results from the finger-prick method with standard blood tests in 100 patients. If the new method works, it could make drug mo…

This study looks at how much radiation reaches tumors and healthy organs during a treatment called 177Lu-PSMA-617 for advanced prostate cancer that has spread. Researchers want to see if the radiation dose can predict how well the treatment works and what side effects might occur…

This study looks at whether measuring the exact radiation dose delivered to tumors can predict which patients with advanced prostate cancer will respond to a targeted radioactive therapy called Lu-177 PSMA. Researchers will track 110 men over 12 weeks to see if dose calculations …

This study sets up Community Living Labs at American Legion posts to help Black men access prostate health services and education. Researchers will see if these labs improve knowledge, screening, and trust. About 250 people, including community health workers and advisors, will t…

This study looks at anxiety levels in men with low-risk prostate cancer who are closely monitored instead of receiving immediate treatment, and also checks how their partners are doing. Researchers will use questionnaires to measure anxiety and find out what factors might predict…

This study looks at whether repeated doses of a gadolinium-based contrast agent (a dye used in MRI scans) affect motor and cognitive functions in healthy adults. About 2076 participants will receive annual imaging and undergo tests over 5 years. The goal is to compare changes in …

This study looks at how a week of either eating less or exercising daily affects prostate tumor growth and muscle health in 45 men with prostate cancer. Participants will be assigned to a reduced-calorie diet, daily exercise with mild diet changes, or their usual routine. After 7…

This study collects blood and leftover tissue samples from 9,600 people with various cancers, including breast, lung, and pancreatic cancer. Researchers will use these samples to improve tests that look for cancer DNA in the blood. The goal is to better detect if cancer returns o…

This study looks at whether a special blood test can find tiny bits of tumor DNA left after prostate cancer surgery. The goal is to see if this test can better predict if the cancer will come back early in high-risk patients. About 50 men with high-risk prostate cancer will give …

This study looks at whether a genetic test can better identify which men ages 55-69 are at risk for serious prostate cancer and which are not. Current screening methods often lead to unnecessary biopsies. The goal is to see if using genetic information can help high-risk men get …

This study tests whether a 3D virtual model, created from PSMA PET scans, can help surgeons better remove lymph node metastases in prostate cancer patients. About 102 participants will undergo surgery with the model used for planning and guidance. Researchers will measure how man…

This study looks at whether a genetic test can help decide which men with prostate cancer can safely have a less invasive treatment called focal therapy, which targets only the tumor instead of the whole prostate. Researchers will enroll 130 men and use the test to classify their…

This study aims to see if a newer, dynamic type of PET scan can find prostate cancer that has spread better than the standard static scan. About 60 men with advanced prostate cancer that is no longer responding to hormone therapy will get both types of scans. The goal is to impro…

This study looks at whether a genetic test can help predict prostate cancer risk in men who have or are at high risk for the disease. Researchers will analyze DNA from 3000 men to find rare and common genetic changes linked to prostate cancer. The goal is to see if this informati…

This study tests whether giving doctors and patients a report generated by artificial intelligence can improve how well risks and benefits of prostate cancer treatments are discussed. About 283 men with newly diagnosed prostate cancer and their doctors will be randomly assigned t…

This study is tracking 3000 men with prostate cancer from Guadeloupe and Brittany to understand why the disease progresses differently in different people. Researchers will collect blood, urine, and saliva samples along with health data to look for genetic, environmental, and lif…

This study looks at how hormone treatments for prostate and breast cancer affect sleep quality. Researchers will monitor 60 patients using sleep tests, activity trackers, and questionnaires before treatment starts, then again at 6 and 12 months. The goal is to understand if these…

This study is testing whether a blood test can detect prostate cancer cells that have spread, similar to a special PET scan. Researchers will take blood samples from 80 prostate cancer patients before their PET scans and compare the results. If the blood test works well, it might…

This study is building a collection of prostate tissue samples from people who carry certain gene mutations (like BRCA1/2) that raise their risk for aggressive prostate cancer. Researchers will compare these samples with those from people without the mutations to learn how the ca…

This study follows 120 men with advanced prostate cancer to see if markers in their blood can predict how well they respond to hormone therapy. Researchers will collect blood samples and compare markers between those who respond well and those who don't. The goal is to develop a …

This study follows over 4,000 men with prostate cancer, some with rare gene mutations (BRCA1, BRCA2, HOXB13, Lynch Syndrome) and some without. Researchers will track their treatment results and survival over time. The goal is to learn whether these mutations affect how the diseas…

This study is testing whether giving breast, prostate, or colorectal cancer survivors a personal referral to a tailored nutrition and exercise program helps them eat better and move more. Participants will use a Fitbit to track activity and sleep, and attend group nutrition sessi…

This study interviews 60 prostate cancer patients and their caregivers to learn about their experiences during and after radiotherapy. The goal is to understand their needs and wishes regarding prehabilitation — preparing for treatment. This is not a treatment trial, but a fact-f…

This study will enroll 5,500 men with high-risk prostate cancer to analyze their tumors at the molecular level. Researchers hope to find biomarkers that predict which treatments work best. Participants will receive standard care, and the study will not test any new drugs.